tetano
Editor, Senior Moderator
Curr Res Transl Med
. 2020 Jun 28;S2452-3186(20)30042-8.
doi: 10.1016/j.retram.2020.06.003. Online ahead of print.
CAR T-cell Treatment During the COVID-19 Pandemic: Management Strategies and Challenges
Yongxian Hu[SUP] 1 [/SUP], Elaine Tan Su Yin[SUP] 2 [/SUP], Yingying Yang[SUP] 3 [/SUP], Hengwei Wu[SUP] 4 [/SUP], Guoqing Wei[SUP] 5 [/SUP], Junwei Su[SUP] 6 [/SUP], Qu Cui[SUP] 7 [/SUP], Aiyun Jin[SUP] 8 [/SUP], Li Yang[SUP] 9 [/SUP], Shan Fu[SUP] 10 [/SUP], Jianfeng Zhou[SUP] 11 [/SUP], Lugui Qiu[SUP] 12 [/SUP], Xi Zhang[SUP] 13 [/SUP], Aibin Liang[SUP] 14 [/SUP], Hongmei Jing[SUP] 15 [/SUP], Yuhua Li[SUP] 16 [/SUP], Didier Blaise[SUP] 17 [/SUP], Mohamad Mohty[SUP] 18 [/SUP], Arnon Nagler[SUP] 19 [/SUP], He Huang[SUP] 20 [/SUP]
Affiliations
Abstract
The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.
Keywords: COVID-19; Chimeric antigen receptor T-cells; Cytokine release syndrome; Immunocompromised; Relapsed/refractory hematological malignancies.
. 2020 Jun 28;S2452-3186(20)30042-8.
doi: 10.1016/j.retram.2020.06.003. Online ahead of print.
CAR T-cell Treatment During the COVID-19 Pandemic: Management Strategies and Challenges
Yongxian Hu[SUP] 1 [/SUP], Elaine Tan Su Yin[SUP] 2 [/SUP], Yingying Yang[SUP] 3 [/SUP], Hengwei Wu[SUP] 4 [/SUP], Guoqing Wei[SUP] 5 [/SUP], Junwei Su[SUP] 6 [/SUP], Qu Cui[SUP] 7 [/SUP], Aiyun Jin[SUP] 8 [/SUP], Li Yang[SUP] 9 [/SUP], Shan Fu[SUP] 10 [/SUP], Jianfeng Zhou[SUP] 11 [/SUP], Lugui Qiu[SUP] 12 [/SUP], Xi Zhang[SUP] 13 [/SUP], Aibin Liang[SUP] 14 [/SUP], Hongmei Jing[SUP] 15 [/SUP], Yuhua Li[SUP] 16 [/SUP], Didier Blaise[SUP] 17 [/SUP], Mohamad Mohty[SUP] 18 [/SUP], Arnon Nagler[SUP] 19 [/SUP], He Huang[SUP] 20 [/SUP]
Affiliations
- PMID: 32620465
- DOI: 10.1016/j.retram.2020.06.003
Abstract
The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.
Keywords: COVID-19; Chimeric antigen receptor T-cells; Cytokine release syndrome; Immunocompromised; Relapsed/refractory hematological malignancies.